ARTHROPLASTY
Erythropoietin reduces the risk of exposure to allogeneic blood transfusion in THA and TKA
Vox Sang. 2016 Oct;111(3):219-225Seven randomized controlled trials were included in this systematic review and meta-analysis to determine the effectiveness of erythropoietin in reducing the risk of exposure to allogenic blood transfusions in patients undergoing total hip and knee arthroplasty procedures. Outcomes assessed were the incidence of allogeneic blood transfusion, units of allogeneic blood transfused, the incidence of adverse events, and cost. The results of this meta-analysis indicated that erythropoietin significantly reduced the risk of exposure to allogenic blood transfusion in both THA and TKA procedures, without increasing the risk of thromboembolic and vascular events. The cost was only evaluated in one study and a pooled estimate could not be calculated.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
